Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
NewsGood news for mammography: a major reanalysis of all eight landmark randomized mammography trials suggests that breast cancer overdiagnosis — detecting cancers that would never cause harm — may be below 5%, far lower than the widely cited 30–50% estimates that have shaped screening debates for decades. Researchers say earlier high estimates failed to account for timing effects, follow-up length, and post-trial screening in control groups.
Mammography's biggest criticism just got a major rethink
For years, one of the loudest arguments against routine breast cancer screening has been overdiagnosis — the idea that mammograms catch cancers that would never have harmed a woman in her lifetime, leading to unnecessary treatment. Some widely cited studies put that risk as high as 30–50%, fueling international debates about whether screening programs do more harm than good.
Now, a sweeping reanalysis from researchers at the University of Southern Denmark, University of Copenhagen, and Queen Mary University of London challenges those figures head-on. By reexamining all eight major randomized mammography trials and comparing them with real-world data from Denmark — where screening was introduced in some regions 17 years earlier than others — the team found overdiagnosis rates consistent with below 5%.
The key insight? Earlier estimates didn't fully account for the timing of cancer diagnoses. When screening starts, diagnoses spike early; later, they dip as those "shifted" cancers are accounted for. Studies that ended before that dip became visible — or that didn't account for control-group women later getting screened — inflated overdiagnosis numbers.
By the Numbers
Why it matters: These findings could reshape how clinicians counsel patients about mammography and how public health bodies communicate screening risks, reinforcing that the life-saving benefits of early detection likely outweigh the risk of unnecessary treatment for the vast majority of women.
